DexCom Inc. Sets New 1-Year High at $30.47 (DXCM)
Shares of DexCom (NASDAQ:DXCM) hit a new 52-week high during trading on Tuesday, AnalystRatingsNetwork.com reports. The stock traded as high as $30.47 and last traded at $29.60, with a volume of 832,306 shares trading hands. The stock had previously closed at $29.04.
Several analysts have recently commented on the stock. Analysts at Benchmark Co. initiated coverage on shares of DexCom in a research note to investors on Tuesday. They set a “buy” rating and a $37.00 price target on the stock. Separately, analysts at Wedbush reiterated a “buy” rating on shares of DexCom in a research note to investors on Monday. They now have a $31.00 price target on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of DexCom in a research note to investors on Friday, September 27th. They now have a $31.00 price target on the stock. Three analysts have rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the stock. DexCom currently has a consensus rating of “Hold” and a consensus price target of $24.02.
DexCom has a 1-year low of $12.03 and a 1-year high of $29.24. The stock has a 50-day moving average of $27.62 and a 200-day moving average of $22.65. The company’s market cap is $2.103 billion.
DexCom (NASDAQ:DXCM) last released its earnings data on Wednesday, August 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.02. The company had revenue of $35.80 million for the quarter, compared to the consensus estimate of $31.14 million. During the same quarter in the previous year, the company posted ($0.21) earnings per share. The company’s revenue for the quarter was up 53.0% on a year-over-year basis. On average, analysts predict that DexCom will post $-0.53 earnings per share for the current fiscal year.
DexCom, Inc (NASDAQ:DXCM) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.